Human Chorionic Gonadotropin (HCG): Research Overview

Human chorionic gonadotropin (HCG) is a glycoprotein hormone produced in large quantities by the syncytiotrophoblast cells of the placenta during pregnancy. It is one of the earliest and most sensitive biochemical markers of pregnancy, detectable in urine and serum within days of implantation. Beyond its role as a pregnancy marker, HCG has well-established clinical applications: it is FDA-approved (as Pregnyl and Novarel) for inducing ovulation in anovulatory women undergoing fertility treatment, for treating hypogonadotropic hypogonadism in males, and for treating prepubertal cryptorchidism. The research literature on HCG in male endocrinology spans more than two decades of controlled studies on intratesticular testosterone maintenance and preservation of spermatogenesis. This overview focuses on these FDA-approved indications and the supporting science. It also explicitly addresses the so-called 'HCG diet,' a pseudoscientific weight-loss program that the FDA has formally warned against, and which has no basis in the approved pharmacology of this hormone.

What Is HCG?

HCG is a heterodimeric glycoprotein consisting of a non-covalently associated alpha subunit (92 amino acids, shared with LH, FSH, and TSH) and a unique beta subunit (145 amino acids) that confers receptor specificity. The beta subunit of HCG shares approximately 85% amino acid sequence homology with the beta subunit of luteinizing hormone (LH) but has a unique 24-amino-acid C-terminal extension heavily decorated with O-linked carbohydrates, which dramatically extends its plasma half-life compared with LH. Pharmaceutical HCG is derived from the urine of pregnant women (urinary HCG) or produced by recombinant DNA technology (choriogonadotropin alfa; brand name Ovidrel). The urinary-derived products Pregnyl and Novarel are administered by intramuscular or subcutaneous injection. Because of its structural and functional similarity to LH, HCG can activate the LH/HCG receptor (LHCGR) on Leydig cells in the testes and on granulosa and theca cells in the ovary.

Mechanism of Action

HCG activates the LHCGR, a G-protein-coupled receptor coupled primarily to Gs proteins. Receptor activation elevates intracellular cyclic AMP (cAMP), activating protein kinase A (PKA), which in turn phosphorylates steroidogenic enzymes and transcription factors that drive testosterone biosynthesis in Leydig cells. In the male, this produces a robust increase in intratesticular testosterone (ITT), which is the local testosterone concentration required to support spermatogenesis — concentrations that are approximately 50–100-fold higher than circulating serum testosterone. This is mechanistically important: exogenous testosterone supplementation suppresses pituitary LH secretion via negative feedback, which removes the endogenous LH signal from Leydig cells and causes intratesticular testosterone to fall, thereby impairing spermatogenesis even when serum testosterone is supraphysiological. HCG bypasses this deficit by directly stimulating Leydig cells, effectively substituting for LH at the testicular level. In the female, HCG mimics the midcycle LH surge to trigger final oocyte maturation and ovulation from a dominant follicle stimulated by exogenous gonadotropins.

What the Research Shows

A foundational study in male HCG pharmacology was conducted by Liu et al. (2002), which examined the dose-response relationship between HCG administration and intratesticular testosterone in men with gonadotropin suppression. This work established that HCG can maintain ITT within or near the physiological range at relatively low doses, providing a pharmacological basis for using HCG as an LH substitute in clinical andrology [1].

Coviello et al. (2005) published the seminal controlled study on low-dose HCG for maintaining ITT in men with experimentally induced gonadotropin suppression (from exogenous testosterone). In a randomized dose-ranging study of 29 healthy men, those receiving low-dose HCG (125–500 IU every other day) alongside testosterone enanthate maintained intratesticular testosterone in the normal range, compared with a marked decline in the testosterone-plus-placebo group. The study demonstrated that as little as 125 IU of HCG every other day was sufficient to maintain normal ITT concentrations (JCEM 2005; 90(5):2595–2602) [2]. This finding has been widely cited in andrology and reproductive endocrinology.

In fertility medicine, HCG is extensively used as an ovulation trigger in controlled ovarian hyperstimulation protocols. Clinical evidence supporting its use in ovulation induction is embedded in decades of assisted reproductive technology (ART) literature; its role as the standard ovulation trigger was established in the 1980s and 1990s. For male hypogonadotropic hypogonadism (e.g., Kallmann syndrome), HCG used alone or in combination with FSH has been shown to restore testosterone and, in many cases, initiate or restore spermatogenesis. Response depends on the duration of hypogonadism and testicular volume at baseline.

Pharmacokinetics

HCG is administered by intramuscular or subcutaneous injection; it is not orally bioavailable because it is a large glycoprotein degraded in the gastrointestinal tract. After intramuscular injection of urinary HCG, peak plasma concentrations are reached in approximately 6 hours, with a biphasic elimination half-life: an initial phase of approximately 5.6 hours and a terminal phase of approximately 23.9 hours. The extended half-life relative to LH (which has a half-life of approximately 30 minutes) is attributable to the extensive N- and O-linked glycosylation of HCG, which reduces hepatic and renal clearance. HCG is primarily eliminated by renal excretion; urinary HCG is the basis for standard pregnancy tests. For the recombinant form (choriogonadotropin alfa / Ovidrel), bioavailability after subcutaneous injection is approximately 40%, with a terminal half-life of approximately 29 hours. There are no significant cytochrome P450 interactions; HCG is cleared by proteolytic degradation following receptor internalization and by renal filtration.

Approved Indications and Clinical Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

HCG is FDA-approved under three indications. For prepubertal cryptorchidism (undescended testes not due to anatomical obstruction), the FDA label for Novarel and Pregnyl specifies the label provides weight-based dosing of 500–5,000 IU intramuscularly (IM) 2–3 times per week for several weeks, as detailed in the full prescribing information, with the label specifying that the schedule should be determined by the treating physician. For hypogonadotropic hypogonadism in adult males, the label specifies 500–1,000 IU IM three times weekly for three or more weeks, followed by the same dose twice weekly, or up to 4,000 IU IM three times weekly for six to nine months in protocols intended to restore testosterone and spermatogenesis. For ovulation induction in women, the label specifies 5,000–10,000 USP units IM one day following the last dose of menotropins. HCG has no FDA approval for weight loss, athletic performance, or body composition [3].

Storage and Handling

Lyophilized (powder) HCG products (Pregnyl, Novarel) should be stored at room temperature (15–30°C / 59–86°F) before reconstitution, protected from light. After reconstitution with the supplied bacteriostatic water, the solution is typically stable for 60 days when refrigerated at 2–8°C. Reconstituted HCG should not be frozen. Choriogonadotropin alfa (Ovidrel prefilled syringe) should be refrigerated at 2–8°C; it may be stored at room temperature below 25°C for up to 30 days. As with all glycoprotein hormone preparations, exposure to elevated temperatures or vigorous agitation can denature the protein and reduce biological activity.

What HCG Is NOT

HCG is not a weight-loss drug. The so-called 'HCG diet' — which pairs extremely low-calorie diets (as low as 500 calories per day) with HCG injections or oral HCG drops — has been the subject of repeated FDA warnings. The FDA, in conjunction with the Federal Trade Commission (FTC), has issued enforcement actions against manufacturers of over-the-counter 'homeopathic' HCG products marketed for weight loss, stating that these products are fraudulent and illegal. The weight loss in HCG diet protocols is attributable entirely to severe caloric restriction, not to HCG. Controlled studies have not demonstrated that HCG enhances fat mobilization, reduces hunger, or produces weight loss beyond that attributable to the accompanying diet. The FDA has been unambiguous: HCG is not approved for and has no demonstrated role in weight management. HCG is also not anabolic in healthy men with intact gonadotropin function; its role is to substitute for LH signal in men with gonadotropin deficiency or suppression. HCG is not a performance-enhancing drug with any established mechanism in athletes with normal physiology, and WADA prohibits its use in competition.

References

[1] Liu PY, et al. Hormonal male contraception: shots in the arm. J Clin Endocrinol Metab. 2002; and related work establishing HCG dose-response for intratesticular testosterone.

[2] Coviello AD, et al. Low-Dose Human Chorionic Gonadotropin Maintains Intratesticular Testosterone in Normal Men with Testosterone-Induced Gonadotropin Suppression. J Clin Endocrinol Metab. 2005;90(5):2595–2602. doi:10.1210/jc.2004-0802.

[3] Novarel (chorionic gonadotropin for injection) FDA label. DailyMed. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ac6918ff-9dc3-40d9-8619-54b26e4bdfc8

[4] Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6087849/